How do you treat patients with metastatic ER+HER2- breast cancer with activating PI3K mutations after progression on everolimus?
Answer from: Medical Oncologist at Academic Institution
Among all HR-positive breast cancer patients, approximately 40% have PIK3CA mutations, making this the most common somatic mutation in this population that could lead to endocrine therapy resistance and disease progression. Our current management of patients with metastatic ER positive breast cancer...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I would still use alpelisib-based therapy, since it’s better tolerated than chemo, and has higher likelihood of response than with experimental treatment.
If we use the notion of a lack of data in patients previously treated with everolimus, then we can’t use either alpelisib or e...